The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing regenerative medicines and advanced therapies. In its 13-year history, ARM has become the voice of the sector, representing the interests of 400+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. To learn more about ARM or to become a member, visit www.alliancerm.org.
Looking to gain extensive exposure to hundreds of top decision makers in the advanced therapies sector? Contact Laura Stringham at lstringham@alliancerm.org to learn more about the benefits of supporting this year’s meeting.
Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. A full-service partner for plasmid DNA, viral vectors, vaccines and autologous and allogeneic cell therapies, Catalent has a global network of small- and large-scale clinical and commercial manufacturing facilities in the U.S. and Europe. www.catalent.com
The complexities of cellular and gene therapy programs present scientific and technical challenges. They are highly customized and vary greatly based on product attributes. Now, because of tremendous promise to cure many types of diseases, there is a lot of pressure to move these programs through regulatory approval faster than ever. It is therefore crucial to find a single partner of choice who offers access to a deep scientific and regulatory network and integrates the various elements of your program to achieve your milestones and make it to market on time. With over 70 years of experience, Charles River has a unique and comprehensive portfolio to support the development and execution of cellular and gene therapy programs from animal model selection to discovery and safety evaluations through to clinical and CMC testing support. www.criver.com
At Lonza Pharma & Biotech, we provide contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need. From the building blocks of life to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome when you expect it. Our extensive track record includes commercialization of pioneering therapies and manufacturing of a wide variety of biological and chemical drugs. We continuously invest to solve not just the current, but also the future challenges. Together, let’s bring your next medicine to life. www.lonza.com
Cellistic traces its origin to a single imperative: we are accelerating allogeneic cell therapy development through reliable manufacturing processes, at lower costs. Through facilities purpose-built for that mission, we help clients simplify their cell therapy development with our iPSC-based technologies and pre-built processes, using our proprietary Pulse & Echo platforms. Our Pulse platform for cell line development provides iPSC and iPSC-based cell lines that are ready for client’s unique edits, to create product-specific working and master cell banks. Our Echo platform for cell therapy manufacturing is centered on a highly efficient family of feeder-free differentiation and expansion processes for NK cells, α/β T cells, γ/δ T cells, macrophages, and other related lineages. The combination of these two platforms ensures customers to cut years of their product development timeline at a much lower cost.
Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 200,000 sq. ft. facility in Columbus, Ohio, The Hearth, to serve as their headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. www.forgebiologics.com
ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. Bringing together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing, ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry. Our platform includes G-Rex® cell culture technology, the Lovo and Cue cell processing systems, and a wide range of GMP proteins, reagents, media, and gene editing technologies. www.scaleready.com
Driven by innovation and built around one of the most prolific academic viral vector manufacturing teams, ViroCell Biologics is focused on supporting therapeutic developers using lentiviral and retroviral vectors from the earliest stages of vector design & optimization through preclinical supply to clinical GMP manufacturing. We are committed to helping companies improve safety and solve the next challenges in cell and gene therapy through our innovation research programs. Our team leverages its deep track record in vector design and innovation to help clients de-risk their products with data-driven vector selection to move to the clinic with confidence. ViroCell’s platform processes and established capabilities enable clients to accelerate their novel therapies into GMP manufacturing and release so that they can reach the clinic quickly and affordably. ViroCell’s MHRA-licensed facility is in London, from which we export globally. Our clients come from all over the world and range from academic investigators to large pharma.
Advanced Medicine Partners delivers what patients deserve and what regulators expect. The company provides partners with process development, manufacturing, analytical development and testing for advanced therapy products, specializing in viral vectors for gene and cell therapies. Advanced Medicine Partners leverages one of the most experienced genetic medicines teams in the industry, and its exclusive manufacturing platform consistently produces yields that are among the highest in the industry and purity profiles that push the boundaries of what’s possible. Advanced Medicine Partners’ proprietary adeno-associated virus (AAV) manufacturing process minimizes impurities and consistently generates industry-leading functional full capsid ratios. This manufacturing process prioritizes patient safety while reducing cost of goods. The company brings extensive operational experience and has manufactured upwards of 350 total non-GMP batches and supplied over 20 preclinical studies, including IND-enabling efficacy and GLP toxicology studies. The team has led CMC efforts for three globally approved gene therapies.
Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. www.adverum.com
Aldevron serves the biotechnology industry with custom production of nucleic acids and proteins. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from research grade to clinical trials to commercial applications. Aldevron specializes in cGMP manufacturing and is known for inventing the GMP-Source® quality system. Aldevron operates the largest cGMP plasmid DNA manufacturing facility in the world at company headquarters in Fargo, North Dakota, with additional facilities in Madison, Wisconsin, and Lincoln, Nebraska. www.aldevron.com
Aseptic Technologies manufactures fill & finish equipment and devices for advanced pharmaceutical manufacturing. Our core expertise lays in the innovation of aseptic filling processes for biopharmaceutical products, including cell and gene therapy products. As a member of SKAN Group, we leverage technological excellence of SKAN in the isolator design, providing integrated solutions for fill & finish projects, globally. Furthermore, we share decades of expertise in injection molding and manufacturing in cleanroom, offering customized ready-to-use assemblies for pharmaceutical processes.
The Cell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies with a vision of a thriving industry delivering life changing advanced therapies to the world. Its aim is to create powerful collaborations which overcome challenges to the advancement of the sector. With over 400 experts covering all aspects of advanced therapies, it applies its unique capabilities and assets, collaborates with academia, industry and healthcare providers to develop new technology and innovation. The Cell and Gene Therapy Catapult works with Innovate UK. ct.catapult.org.uk | http://www.gov.uk/innovate-uk
Cryoport is the life sciences industry’s most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR T-cells. Cryoport’s solutions are used by points-of-care, CROs, central laboratories, pharmaceutical companies, manufacturers, university researchers; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport’s proprietary Cryoport Express® Shippers, Cryoportal® Logistics Management Platform, leading-edge Smartpak II® Condition Monitoring System, and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts. www.cryoport.com
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI is currently part of more than 30 active COVID-19 projects for treatment and prevention. CTI also offers a fully integrated multi-specialty clinical research site, as well as complete global laboratory services. Now in its third decade, it is one of the 20 largest CROs in the world with associates in more than 60 countries across six continents. The company was recently named the #1 CRO in the world for quality at the 2020 CRO Leadership Awards, outperforming nearly 30 other recognized CROs from around the world. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, MEA and Asia-Pacific. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations and for moving medicine forward. www.ctifacts.com
At Dark Horse Consulting Group, we specialize in the development of cell and gene therapy products. All of our consultants have deep cell and gene therapy industry experience, spanning diverse functions including process development, device development, manufacturing, preclinical development, quality, regulatory, program management, business development, strategy, intellectual property, and financing/investor relations. Many of our consultants also bring experience from adjacent more mature sectors, including traditional biologics, small molecules, medical devices, and management consulting. As a result, we understand the unique challenges faced by cell and gene therapy developers and are able to apply best practices from other industries to address the needs of our clients. Our team of cell and gene therapy professionals bring deep technical expertise to help you tackle the unique challenges of our exciting young field. www.darkhorseconsultinggroup.com
EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our seven landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today our events (BIO-Europe, BIO-Europe Spring, BioPharm America, Biotech Showcase, ChinaBio Partnering Forum, Cell & Gene Exchange, and BioEquity Europe) annually attract more than 12,000 senior life science executives who engage in over 43,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry. www.ebdgroup.com
GeneFab is a contract research and manufacturing organization focused on cell and gene therapies. GeneFab was formed in 2023 with a vision to combine industry leading expertise in synthetic biology with advanced cGMP capabilities in order to accelerate the development and commercialization of genetic medicines. GeneFab capabilities spans early stage product design, technical development and cGMP compliant production including CAR-T/CAR-NK Cells, iPSCs, engineered cell banks, AAV, lentiviral vectors, gamma-retroviral vectors, mRNA, LNP and pDNA. GeneFab’s technology platform includes bioinformatic-guided discovery of cell type promoters, directed evolution of small molecule-regulated gene switches, the engineering of highly sensitive kill switches for enhanced safety and control of cellular therapies, and innovator-centric manufacturing platforms to accelerate novel therapies to patients in need. Across two facilities in Alameda and South San Francisco and facility soon in Singapore, GeneFab employs approximately 100 employees, including experts in cell, gene, and nucleic acid therapy, CMC, analytical development, process development and synthetic biology.
GlobalData is a trusted and authoritative intelligence provider to the world’s largest industries. We cover a broad spectrum of the pharmaceutical, medical technology and healthcare value systems with in-depth analysis, forecasts, exclusive news, and robust databases all available through a fully integrated platform. Our Consulting team expands on the company’s intelligence offering and serves our clients as strategic advisors. The team combines a global presence with the extensive industry expertise required to ask the right questions and uncover strategic insights, thereby allowing our clients to anticipate and plan for the market events likely to impact their future success. www.globaldata.com
Invetech helps solve commercial manufacturing challenges for the global cell and gene therapy market. With dozens of successful collaborations with the world’s leading regenerative medicine companies over the past 20 years, we’re a proven partner committed to helping you successfully transition from clinical to commercial-scale manufacturing. Our automation platforms and manufacturing systems provide Assured Pathways™ to integrated commercial manufacturing, from pre-clinical phase to large-scale manufacturing, without any substantive process changes. We configure solutions and provide the systems and resources you need to achieve large-scale, end-to-end cell and gene therapy manufacturing with a single point of accountability. www.invetechgroup.com
L7 Informatics reimagines data intelligence for modern life sciences and healthcare organizations. Beyond data management, L7 provides tools that optimize the flow of information between data, processes, and people, unlocking innovation at every stage of the clinical, research, and manufacturing value chains. Our comprehensive operating environment and software stack bring flexible, secure, and collaborative data intelligence to your entire operation. From regulatory compliance and workflow orchestration to customized applications and integrations, our end-to-end transformation engine helps organizations solve the challenges of today and realize the opportunities of tomorrow. L7 Informatic’s Enterprise Science Platform (L7|ESP) is designed to solve today’s life science and biopharmaceutical industry challenges with cell and gene therapy processes that have limited workflow automation and critical data compliance requirements. Siloed multi-vendor IT systems make it challenging to create an integrated and validated environment for biologics manufacturing with processes involving a mixture of paper, software systems, instruments, environmental monitoring systems, and bioprocess equipment. L7|ESP is a unique regulatory compliant platform that provides an integrated software platform for digitalizing the sample to drug process with features including equipment integration, EBR, MES, CPV, inventory, sample/ location management, and analytics/statistical processing with reports and dashboard and QC LIMS. www.l7informatics.com
MaxCyte is a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past twenty years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use, more cost-effectively and with lowered risk. Our broad intellectual property (IP) portfolio, along with our regulatory certifications and support, offer our partners both enhanced IP protection and freedom to operate. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, U.S. www.maxcyte.com
RoslinCT is a leading Cell Therapy Contract Development and Manufacturing Organisation (CDMO), enabling you to safely bring your autologous or allogeneic therapy to patients. We operate a fully licensed GMP manufacturing facility and have a proven track record in the delivery of cell-based products. We offer a range of integrated services from technology transfer, process, and assay development through to GMP manufacturing, storage, QP certification, and batch release of cell-based therapies for clinical trials. We also engage with leading cell and gene therapy developers providing a personalised service. At the heart of RoslinCT is a dynamic, highly experienced team that will understand your goals and will partner with you to get your therapy to market efficiently and effectively. We put quality and integrity at the heart of the business to make sure we provide you with the trust that your life-changing therapy is on the right pathway to commercialisation. www.roslinct.com
A critical factor facing the industry is choosing technologies and partners that can deliver scale. The challenges inherent in translating early clinical trials to a reproducible and robust process suitable for scalable commercial production are very significant. Each personalized drug product ultimately depends on a sustainable and consistent supply chain with lots of moving parts. Configured to your exact demands, using an industry-standard framework, TrakCel’s comprehensive supply chain platform ensures every resource is managed, monitored, recorded, and is ultimately performed exactly as required. From sample collection through logistics, manufacturing, and final transplantation, with comprehensive chain of custody, chain of identity, and traceability, TrakCel’s proven technology integrates and orchestrates every aspect of your autologous and allogeneic supply chains in a scalable, compliant, and validated technology platform. www.trakcel.com
Wacker Biotech is “YOUR MICROBIAL CDMO FOR ADVANCED THERAPEUTICS” – partner of choice for process development and commercial manufacturing of biopharmaceuticals (therapeutic proteins, vaccines, live microbial products, and plasmid DNA (pDNA)) using microbial hosts. Developed over decades, PLASMITEC®, our plug-and-play platform for pDNA is suitable for manufacturing R&D supplies (non-GMP) up to scale-up to full GMP-compliant production. Additionally, WACKER BIOTECH provides R&D and GMP manufacturing services for advanced therapies as a one-stop-shop: from the production of plasmid and template DNA as starting material for mRNA through the IVT of mRNA and LNP formulation. Wacker Biotech maintains four GMP-compliant, FDA- and EMA-certified production plants in Amsterdam (The Netherlands), San Diego (US) and in the German cities of Jena and Halle. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly-owned subsidiaries of the Munich-based WACKER Group. www.wacker.com/biologics
Right. On Time. AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), providing world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast track projects for orphan drugs and rare diseases. www.agcbio.com
Akron Bio enables the advancement of cell and gene therapies through its portfolio of cytokines and media supplements, as well as its comprehensive suite of manufacturing services, including the production of plasmid DNA, precision gene-editing tools, and specialized medias. Akron partners with advanced therapy developers, providing them with critical materials and services at the scale, level of compliance, and regulatory support necessary to drive novel treatments from discovery to commercialization, thereby addressing critical unmet needs in the patient community. www.akronbiotech.com
Anocca is leveraging its innovative platform approach to develop transformative T Cell Receptor (TCR) engineered-T cell (TCR-T) immunotherapies to treat solid tumours. The company has validated and deployed a proprietary precision biology platform that enables assumption-free discovery of targets and fully characterised TCRs at an industrial scale with unmatched speed and precision. Anocca has a fully integrated R&D infrastructure, underpinned by tailor-made advanced software solutions, and complemented by an in-house clinical manufacturing and process development facility. The platform has generated a broad preclinical pipeline of asset libraries with blockbuster potential and expects to progress to the clinic in the near term. Founded in 2014, Anocca is led by an experienced management team that has raised over USD 125 million in funding from a small group of investors that includes the European Investment Bank. Anocca’s team of around 100 employees operate from its site in Södertälje, Sweden. www.anocca.com
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases.
www.autolus.com
CoJourney offers an exceptional CDMO experience, specializing in process development and cGMP manufacturing of Plasmids, Viral Vectors, and mRNA. Our high-quality manufacturing platforms have earned the trust of over 40 satisfied gene therapy customers. We are your partner in the Gene Therapy journey, offering Plasmids ready in 4 months (from development to GMP release), Viral Vectors in 5 months (from Plasmids through GMP release), and mRNA in 5 months (from plasmids development to GMP release).
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX: CSL | USOTC: CSLLY), headquartered in Melbourne, Australia, employs more than 27,000 people, and delivers its life-saving therapies to people in more than 100 countries. Visit our website or follow us on Twitter for inspiring stories about the promise of biotechnology.
Cytiva is a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics. Cytiva’s diverse portfolio includes well-recognized brands such as ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Whatman and Xcellerex. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the delivery of transformative medicines to patients. www.cytiva.com
ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, BaseCamp is a purpose-built facility offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities. Through BaseCamp and its enabling technologies, ElevateBio is focused on growing its collaborations with industry partners while also developing its own portfolio of cellular and genetic medicines. ElevateBio’s team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare. www.elevate.bio
Evotec is a biotechnology company focused on delivering highly effective new therapeutics to patients. The Company leverages its multimodality platforms for proprietary projects and pipeline co-creation with partners including Pharma, Biotech, academics, and other healthcare stakeholders. Our business model is flexible, ranging from service-based support to strategic partnerships. Evotec offers a fully integrated end-to-end platform to move iPSC-based cell therapy projects from inception to the clinic, including in-house GMP manufacturing capabilities with clinical supply. Our proprietary iPSC-based cell therapy pipeline is one of the broadest in the industry and includes anti-tumor therapies (NK cells, macrophages, αβ T cells, γδ T cells), regenerative therapies (beta cells, cardiomyocytes, photoreceptors) and immune-modulation therapies. In addition, Evotec provides integrated drug development solutions, covering safety assessment, CMC, process and analytical development, regulatory and clinical services for autologous and allogeneic cell therapy candidates.
Form Bio, a life sciences technology company, offers an award-winning research and discovery platform alongside robust AI solutions for accelerating the research and development of genetically modified therapies in biopharma and biotech. Beyond delivering innovative technology, Form Bio collaborates closely with customers to advance their scientific goals. The company brings unparalleled cross-disciplinary expertise, covering software engineering, biology, bioinformatics, and data science.
Fred Hutchinson Cancer Center (Fred Hutch) is an independent, nonprofit, unified adult cancer care and research center that is clinically integrated with UW Medicine, a world leader in clinical care, research and learning. Fred Hutchinson Cancer Center was created in April 2022 by the merger of long-time partners, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance. Together, our fully integrated research and clinical care teams seek to discover new cures for the world’s deadliest diseases and make life beyond cancer a reality. The first National Cancer Institute-designated cancer center in the Pacific Northwest, Fred Hutch’s global leadership in bone marrow transplantation, HIV/AIDS, immunotherapy and COVID-19 has confirmed our reputation as one of the world’s leading cancer, infectious disease and biomedical research centers. Based in Seattle, Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services, and has network affiliations with hospitals in five states. www.fredhutch.org
Mekonos is a CGT platform company building the future of cell therapies on a chip. The company’s System on a Chip merges innovations in semiconductor technology, microfluidics, and chemistry for controlled and individualized molecular delivery in cells at scale, offering an integrated solution for advanced cell and gene therapy development from R&D through Manufacturing. Mekonos’ ex vivo delivery technology uses silicon nanoneedles to gently and efficiently deliver cargo into any cell type, including primary immune cells, iPSCs and HSCs, with very high viability. The company’s nanoneedle-based delivery system — one needle, one cell — offers single-cell precision at scale, with a level of control and consistency unachievable with conventional delivery technologies. The Mekonos platform enables unique cell engineering capabilities, including nuclear delivery, sequential editing, multiplexing and dose control for hyper-precise ex-vivo delivery. The company is headquartered in Alameda, CA and is backed by leading investors in both healthcare and technology. www.mekonos.com
Rare diseases include some of the most serious of all illnesses and impact millions of patients worldwide, representing an opportunity to apply our knowledge and expertise to help make a significant impact on addressing unmet medical needs. The Pfizer focus on rare disease builds on more than two decades of experience, a dedicated research unit focusing on rare disease, and a global portfolio of multiple medicines within a number of disease areas of focus, including rare hematologic, neurologic, cardiac and inherited metabolic disorders. Pfizer Rare Disease combines pioneering science and deep understanding of how diseases work with insights from innovative strategic collaborations with academic researchers, patients, and other companies to deliver transformative treatments and solutions. We innovate every day leveraging our global footprint to accelerate the development and delivery of groundbreaking medicines and the hope of cures. Learn more about our Rare Disease portfolio and how we empower patients, engage communities in our clinical development programs, and support programs that heighten disease awareness. www.pfizer.com/science/rare-diseases
Viralgen is a CDMO specializing in the production of recombinant Adeno-Associated Viral vectors. Viraglen was created in 2017 to respond to the unmet need for manufacturing of gene therapies, with the goal to help broaden access to these life-saving therapeutics and to contribute to the advancement of health and human welfare around the world. We have built an optimized facility in San Sebastian, Spain that maximizes throughput and efficiency of our proprietary Pro10™ suspension manufacturing platform, enabling industry-leading scalability, reproducibility, and speed to market. Through our superior technology platform, we deliver industry-leading titers and cGMP-certified quality for all AAV serotypes to our client partners, optimizing the cost-of-goods and accelerating clinical development and commercialization of life-changing genetic medicines. www.viralgenvc.com
Virica develops viral enhancers which optimize the manufacturing of viral medicines, allowing developers to economically deploy their products at scale. Virica’s Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by innate antiviral defenses in manufacturing cells. Our purpose developed VSE formulations substantially increase manufacturing yields and reduce the cost of goods for a range of products, including vaccines, gene therapies, and cell therapies. www.viricabiotech.com
Gift of Life Biologics is uniquely best positioned to support innovators of allogeneic cell and gene therapies sourcing high quality healthy donor starting material across all stages from research use to global therapeutic commercialization. Gift of Life Biologics is vertically integrated offering access to a world-renowned international registry with over 450,000 healthy donors with on-site capabilities including apheresis, laboratory, cell processing and isolation, and GMP ISO class 7 clean rooms.
Rapid Micro Biosystems® (RMB) creates, sells, validates, and services innovative products for fast, accurate, and efficient detection of microbial contamination in the manufacture of cell and gene therapies, pharmaceuticals, biologics, biotechnology products, medical devices, and personal care products. The company’s Growth Direct® is the only fully automated, non-destructive growth-based system for multiple QC test applications: environmental monitoring, water, bioburden, and sterility testing. Automating rapid compendial QC micro testing ensures data integrity, compliance, and operational efficiencies. RMB is dedicated to providing groundbreaking technology and products to support companies in their journey to achieve greater reliability, efficiency, and better predictability, ultimately providing higher quality products for improved patient outcomes.
ASEBIO is the Spanish Bioindustry Association. ASEBIO brings together companies, associations, foundations, universities, research and technology centers that carry out activities directly or indirectly related to biotechnology in Spain. Since 1999, ASEBIO has been acting as a meeting and promotion platform for those organizations interested in stimulating the national biotechnology scene. In order to do this, ASEBIO works closely with regional, national, and European governments as well as all the social organizations interested in using biotechnology to improve quality of life, the environment, and generating skilled employment. www.asebio.com/en
The BioIndustry Association (BIA) is the trade association for innovative life sciences and biotech industry in the UK, counting over 500 companies including start-ups, biotechnology, universities, research centres, investors and lawyers among its members. Our mission is to be the voice of the industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation. www.bioindustry.org
The FreeMind Group is the premier international consulting firm specializing in assisting life science organizations to secure non-dilutive funding from U.S. federal agencies and private foundations. Founded in 1999, The FreeMind Group is the largest consulting group of its kind and works with a variety of life sciences organizations, from small startups to large pharmaceutical companies. FreeMind’s proven long-term strategic approach has garnered its clients over $1.5 billion to date in non-dilutive funding. The FreeMind team combines their extraordinary scientific understanding, innovative business and financial expertise and creative writing and presentation skills to cater to the specific and unique needs of academic and research institutions as well as the life science industry. www.freemindconsultants.com
April 9-11, 2024
Rome Cavalieri
Via Alberto Cadlolo 101
Rome, Italy
